依那西普(Etanercept) - 药物靶点：LTα x TNF-α_在研适应症：银屑病，非放射性轴性脊柱关节炎，多关节型幼年特发性关节炎_专利_临床

概要

基本信息

药物类型

融合蛋白

别名

Etanercept (Genetical Recombination)、Etanercept BS、RHU TNFR:FC

+ [8]

靶点

LTα x TNF-α

作用方式

抑制剂

作用机制

LTα抑制剂(肿瘤坏死因子β抑制剂)、TNF-α抑制剂(肿瘤坏死因子α抑制剂)

治疗领域

免疫系统疾病感染皮肤和肌肉骨骼疾病+ [1]

在研适应症

银屑病非放射性轴性脊柱关节炎多关节型幼年特发性关节炎+ [8]

非在研适应症

肢端弹力样变腺癌晚期恶性实体瘤+ [20]

原研机构

Amgen, Inc.

在研机构

C.H. Boehringer Sohn AG & Co. KGPfizer Europe MA EEIG

Takeda Pharmaceutical Co., Ltd.

+ [4]

非在研机构

Amgen, Inc.

Pfizer Inc.Hanwha Chemical (Thailand) Co., Ltd.

+ [2]

最高研发阶段批准上市

首次获批日期

美国 (1998-11-02),

类风湿关节炎

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 38320

来源: *****

关联

376

项与依那西普相关的临床试验

NCT06016517

/ Not yet recruitingN/AIIT

Application of the Personalized N-of-1 Trial Design in Patients with Rheumatoid Arthritis

The goal of this N-of-1 study is to learn about treatment for individual patients who have rheumatoid arthritis (RA,) for which many treatments are available. The treatments are different in how they work, the way they are given, side- effects, and cost. While treatment guidelines are available, finding the best treatment order of treatments is often based on physician choice. The main question this study aims to answer are:
* What are the effects of different treatments on RA symptoms and condition for each individual patient
* What is the effectiveness of different treatments across all patients enrolled in the N-of-1 study
Participants will be enrolled and randomized to a sequence of three U.S. Food and Drug Administration (FDA) approved RA medications: 1. etanercept, 2. adalimumab, 3. upadacitinib 4. tocilizumab. Participants will be asked to complete questionnaires about their condition and quality of life weekly (either in clinic or remotely) and report their level of pain daily (remotely).

开始日期2025-05-15

申办/合作机构

Tufts Medical Center, Inc.

CTIS2023-506623-29-01

/ Recruiting临床2期

A randomized trial comparing efficacy and safety of etanercept and methotrexate in giant cell arteritis (EFFECTA) - ABM/EFFECTA/2023

开始日期2025-03-12

申办/合作机构

Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy

NCT06707194

/ Not yet recruiting临床4期IIT

Effect and Safety of Benzathine Penicillin Combined With Etanercept on Spondyloarthritis: a Multicenter Randomized Controlled Clinical Study

The purpose of the study is to verify the clinical feasibility of Benzathine penicillin (BPG) /Etanercept (ETN) combination regimen in patients with spondyloarthritis (SpA) and at the same time compare Benzathine penicillin /Etanercept combination regimen and Etanercept maintenance therapy in reducing disease activity, improving patients' clinical symptoms and body function scores, enhancing quality of life, improving imaging performance and safety.

开始日期2025-03-01

申办/合作机构

南方医科大学南方医院

100 项与依那西普相关的临床结果

登录后查看更多信息

100 项与依那西普相关的转化医学

登录后查看更多信息

100 项与依那西普相关的专利（医药）

登录后查看更多信息

8,384

项与依那西普相关的文献（医药）

2025-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Successful treatment of etanercept- and adalimumab-resistant pyoderma gangrenosum with spesolimab, moderate-dose corticosteroids, and minocycline

Article

作者: Zhang, Hanlin ; Wu, Chao ; Jin, Hongzhong

PURPOSE:

Pyoderma gangrenosum (PG) is a rare, neutrophilic dermatosis characterized by rapidly developing, painful ulcers. This study explores the potential of spesolimab, an anti-IL-36R antibody, as a therapeutic option for refractory PG.

MATERIALS AND METHODS:

We report a case of a 48-year-old male with refractory PG who failed to respond to etanercept and adalimumab. Upon admission, the patient presented with extensive, painful ulcerations on the trunk and extremities. He was started on oral methylprednisolone (32 mg/day) and minocycline (50 mg twice daily). After a week, minimal improvement was observed. After reviewing the screening results and discussing treatment options, the patient received two doses of spesolimab (900 mg intravenously) administered two weeks apart.

RESULTS:

Marked clinical improvement was observed after spesolimab initiation. Complete ulcer healing was achieved within six weeks of starting spesolimab, with no adverse effects reported.

CONCLUSIONS:

This case demonstrates the potential efficacy of spesolimab for treating refractory PG, particularly in patients unresponsive to TNF-α inhibitors. Despite the added complexity of the patient's underlying HBV infection and elevated M-protein, no HBV reactivation or other hematologic complications occurred. Further studies are needed to validate its role in managing PG and other neutrophilic dermatoses.

2025-05-01·IMMUNOBIOLOGY

Mechanism and Efficacy of Etanercept in Treating Autoimmune-like Manifestations of Coronavirus Disease 2019 in elderly individuals

Article

作者: Geng, Jie ; Li, Zhilun ; Pu, Hongbin ; Guo, Bo ; Li, Chenghui ; Li, Hongyi ; Yu, Qi ; Zhao, Peng ; Zhai, Bing ; Xiao, Yang ; Hou, Chuandong ; Gao, Chumeng ; Chen, Haoran ; Zhang, Lizhong ; Zhang, Haojun ; Yang, Bo ; Lu, Jinqi ; Song, Xia ; Bao, Zhuocheng ; Lu, Xuechun ; Shi, Lei

During the COVID-19 pandemic, extensive research focused on universal treatments, but few studies addressed treatment regimens for elderly patients. This study aimed to evaluate the effects of etanercept, a TNF inhibitor, in elderly individuals with COVID-19 through observational analysis of compassionate use cases. The results showed that after one month of etanercept treatment, clinical indicators such as C-reactive protein, D-dimer, and fibrinogen normalised, whereas the control group receiving conventional treatment did not fully recover. Single-cell sequencing was performed on seven patients treated with etanercept and two uninfected individuals. Based on our data and in conjunction with external data, a comprehensive characterization map involving 400,000 cells was created. Transcriptomic analysis revealed autoimmune-like manifestations in elderly patients, highlighting the importance of immunotherapy. Plasma cells, platelets, and B cells were the most treatment-sensitive cells. Analysis of five drug types, including antiviral, etanercept, glucocorticoids, tocilizumab, and others, showed that tocilizumab was associated with an increased thrombosis risk in elderly patients. Meanwhile, etanercept alleviated autoimmune-like manifestations by inhibiting platelet factor 4 and suppressing TNF-α. Molecular docking showed etanercept's strong affinity (-15.0 kcal/mol) for the spike protein of the SARS-CoV-2 Omicron variant, suggesting it may protect immune-compromised patients. Our findings support etanercept as a potential treatment for elderly COVID-19 patients with autoimmune-like manifestations.

2025-05-01·JOURNAL OF AUTOIMMUNITY

Treatment of uveitis in Blau syndrome: A systematic review and meta-analysis

Article

作者: Simonini, Gabriele ; Pagnini, Ilaria ; Marrani, Edoardo ; Wouters, Carine ; de Masi, Salvatore ; Rosè, Carlos D ; Maccora, Ilaria ; Maniscalco, Valerio ; Mastrolia, Maria Vincenza

OBJECTIVES:

Blau syndrome (BS) is a rare autoinflammatory disease caused by gain of function variants in NOD2. Uveitis is one of the triad features with arthritis and dermatitis. Management of uveitis is challenging, and uncontrolled uveitis may lead to blindness. We aim to evaluate the evidence regarding effectiveness of systemic treatments, including conventional Disease Modifying anti-Rheumatic drugs(cDMARDs) and biologic DMARDs(bDMARDs), for the management of uveitis in BS.

METHODS:

A systematic literature review and meta-analysis was performed according to PRISMA guidelines. Papers were selected if they reported patients with BS and uveitis who received systemic treatment. Papers were selected if reporting efficacy according to Standardization of Uveitis Nomenclature (SUN) criteria.

RESULTS:

We identified 1205 papers with 11 selected for systematic review and meta-analysis. Among the 11 selected papers, we identified 88 treatments. Among these, 53 were cDMARDs (36 methotrexate, 7 azathioprine, 5 mycophenolate, 3 thalidomide, 1 tacrolimus and 1 cyclosporine) and 35 bDMARDs (23 adalimumab, 6 infliximab, 4 etanercept, 1 golimumab and 1 canakinumab). The proportion of children showing improvement of uveitis was 20 % (95 % CI 2-46) and 22 % (95 % CI3-47) for cDMARDs and bDMARDs respectively (χ²0.23, p = 0.631). No differences were observed among the administered drugs (χ²7.21, p = 0.706).

CONCLUSION:

The data show that there is not enough evidence to establish a preferred treatment for managing uveitis in BS. Considering the rarity, the potential severity and refractoriness to current treatments of the disease, there is a critical need for better understanding of pathophysiology and expert driven treatment guidelines for of BS-uveitis.

357

项与依那西普相关的新闻（医药）

2025-04-15

·echemi

Sandoz Challenges Amgen’s $3.3B Arthritis Drug Monopoly in U.S. Antitrust Lawsuit

Swiss pharmaceutical company Sandoz has initiated a legal battle against U.S. biotech giant Amgen, accusing it of unlawfully maintaining a monopoly over the arthritis medication Enbrel (etanercept). Filed in a federal court in Norfolk, Virginia, the lawsuit alleges that Amgen has employed a “thicket of patents” to block competition from biosimilars, including Sandoz’s Erelzi, effectively extending its market dominance through 2029. Despite receiving FDA approval for Erelzi in 2016, Sandoz claims it has been unable to enter the U.S. market due to Amgen’s patent strategies. The company argues that this has resulted in billions of dollars in profits for Amgen while denying patients access to more affordable alternatives. In 2024 alone, Enbrel generated $3.3 billion in U.S. revenue. Sandoz is seeking an injunction to lift the patent barriers and is also requesting financial damages. Amgen has yet to respond to the lawsuit.

专利侵权

2025-04-14

·GlobeNewswire-Health Care

[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules – corrected: reference to date of product launch in Europe removed; link to “Important Safety Information” updated Company aims to accelerate access to much-needed biosimilar to reference medicine Enbrel®* for US patients with disabling inflammatory diseasesDespite FDA approval nearly a decade ago, etanercept biosimilar continues to be blockedSandoz seeking damages in addition to clearing path for launch Basel, April 14, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced the filing of an antitrust lawsuit in the US against Amgen, Inc. (Amgen), for extending and entrenching the dominant market position of its blockbuster medicine, Enbrel® (etanercept), first approved by the US Food and Drug Administration (FDA) in 1998. Etanercept is a biologic medicine used to treat a range of disabling inflammatory diseases. Sandoz alleges that Amgen blocked competition from more cost-effective biosimilar competitors, including Sandoz etanercept biosimilar, Erelzi®+ (etanercept-szzs), by unlawfully purchasing and using certain patent rights to entrench its position in the market. In 2024, Enbrel® generated USD 3.3 billion in revenue in the US[1]. Sandoz received US FDA approval for Erelzi® in 2016. Today, Amgen is continuing to block entry of this important treatment option for approximately 7.5 million Americans living with chronic inflammatory diseases, including rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis[2-6], many of whom could benefit from the cost savings and expanded access resulting from the introduction of high-quality, more-affordable biosimilar options. Sandoz is seeking an injunction to prevent Amgen from using certain patent rights to block biosimilar competition and allow Sandoz to launch Erelzi® as soon as possible. The company is also seeking damages, which could be tripled under applicable laws. The lawsuit was filed in the US District Court for the Eastern District of Virginia. *Enbrel® is a registered trademark of Amgen, Inc.+Erelzi® is a registered trademark of Sandoz Inc. About Erelzi® (etanercept-szzs)Erelzi® is the Sandoz biosimilar of the reference medicine Enbrel®. Erelzi® has been studied in a global development program, which included a comprehensive comparison of Erelzi® and Enbrel® at the analytical, preclinical, and clinical levels. The program included preclinical studies, pharmacokinetic (PK) studies, and the Phase III confirmatory safety and efficacy EGALITY study. Erelzi® is approved by the US FDA for the following indications: adult rheumatoid arthritis (RA), ankylosing spondylitis (AS), polyarticular juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA) and moderate to severe plaque psoriasis (PsO). IMPORTANT SAFETY INFORMATIONPlease see full Prescribing Information for Erelzi® here. DISCLAIMERThis Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law. ABOUT SANDOZ Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 900 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2024, Sandoz recorded net sales of USD 10.4 billion. REFERENCES 1. Statista. Revenue of Amgen’s Enbrel by Region from 2011-2014. Available at: Revenue Enbrel worldwide by region 2024 | Statista [Last accessed: March 2025]2. Xu Y, Wu Q. Prevalence Trend and Disparities in Rheumatoid Arthritis among US Adults, 2005-2018. J Clin Med. 2021;10(15):3289. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC8348893/ [Last accessed: March 2025]3. Johns Hopkins Arthritis Center. Ankylosing Spondylitis. Available at: https://www.hopkinsarthritis.org/arthritis-info/ankylosing-spondylitis/ [Last accessed: March 2025]4. About Juvenile Idiopathic Arthritis. Available at: https://www.arthritis.org/getmedia/6398ed64-029b-4629-82e7-bf91fa61d8f5/Juvenile-Idiopathic-Arthritis-JIA-FactSheet-101122.pdf [Last accessed: March 2025]5. National Psoriasis Foundation. Psoriasis Statistics. Available at: https://www.psoriasis.org/psoriasis-statistics [Last accessed: March 2025]6. Weiss PF. Polyarticular juvenile idiopathic arthritis: Clinical manifestations, diagnosis, and complications. Available at: https://www.uptodate.com/contents/polyarticular-juvenile-idiopathic-arthritis-clinical-manifestations-diagnosis-and-complications [Last accessed: March 2025] CONTACTS Global Media Relations contactsInvestor Relations contactsGlobal.MediaRelations@sandoz.comInvestor.Relations@sandoz.comAlex Kalomparis+41 792 790285Craig Marks+44 781 8 94 2383Joerg E. Allgaeuer+49 171 838 4838Rupreet Sandhu+41 791 05472US Media Relations contacts Media.Info@sandoz.com Vicki Crafton+1 201 213 6338 Attachment Media release_Etanercept Amgen Antitrust Litigation_corrected

上市批准临床3期生物类似药专利侵权临床结果

2025-04-14

·健识局

新事 | 山德士对安进提起反垄断诉讼

4月14日，瑞士仿制药生产商山德士宣布：在美国向安进提起反垄断诉讼，指控其通过不正当方式维持市场垄断地位。山德士声称，安进公司通过非法购买和使用某些专利权来巩固其市场地位，阻碍山德士等企业的依那西普生物类似药参与市场竞争。依那西普是安进的重磅药物，早在1998年就获得FDA批准上市，主要用于治疗类风湿关节炎、银屑病、银屑病关节炎等致残性炎症疾病。依那西普在美国市场一直占据着主导地位，2024年在美国还实现了33亿美元的收入。2023年的调研数据显示，依那西普的市场价格相比上市之初已经上涨了701%，而美国专利要到2029年才到期。山德士早就开发了依那西普的生物类似药，而且在2016年获得了美国FDA的批准，但批准近十年，这款生物类似药依然没能进入美国市场。撰稿丨李傲编辑丨江芸贾亭运营｜雾纪声明：健识局原创内容，未经许可请勿转载中药企业将退市；第十批集采落地进度汇总；水痘疫苗价格暴跌你敢信么？降脂新药打一针能管一年半FDA立新规矩，昭衍新药受伤

生物类似药专利到期疫苗

100 项与依那西普相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00742	依那西普	L04AB01	DB00005

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
银屑病	中国	C.H. Boehringer Sohn AG & Co. KG	2010-02-26
非放射性轴性脊柱关节炎	澳大利亚	Pfizer Australia Pty Ltd.	2003-03-18
多关节型幼年特发性关节炎	美国	Immunex Corp.	2002-01-15
强直性脊柱炎	欧盟	Pfizer Europe MA EEIG	2000-02-02
强直性脊柱炎	冰岛	Pfizer Europe MA EEIG	2000-02-02
强直性脊柱炎	列支敦士登	Pfizer Europe MA EEIG	2000-02-02
强直性脊柱炎	挪威	Pfizer Europe MA EEIG	2000-02-02
银屑病关节炎	欧盟	Pfizer Europe MA EEIG	2000-02-02
银屑病关节炎	冰岛	Pfizer Europe MA EEIG	2000-02-02
银屑病关节炎	列支敦士登	Pfizer Europe MA EEIG	2000-02-02
银屑病关节炎	挪威	Pfizer Europe MA EEIG	2000-02-02
中轴性脊柱关节炎	欧盟	Pfizer Europe MA EEIG	2000-02-02
中轴性脊柱关节炎	冰岛	Pfizer Europe MA EEIG	2000-02-02
中轴性脊柱关节炎	列支敦士登	Pfizer Europe MA EEIG	2000-02-02
中轴性脊柱关节炎	挪威	Pfizer Europe MA EEIG	2000-02-02
附着点炎相关关节炎	欧盟	Pfizer Europe MA EEIG	2000-02-02
附着点炎相关关节炎	冰岛	Pfizer Europe MA EEIG	2000-02-02
附着点炎相关关节炎	列支敦士登	Pfizer Europe MA EEIG	2000-02-02
附着点炎相关关节炎	挪威	Pfizer Europe MA EEIG	2000-02-02
幼年特发性关节炎	欧盟	Pfizer Europe MA EEIG	2000-02-02

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
疼痛	临床3期	美国	Amgen, Inc.	2016-11-29
疼痛	临床3期	波多黎各	Amgen, Inc.	2016-11-29
青少年少关节慢性关节炎	临床3期	澳大利亚	Pfizer Inc.	2009-09-01
青少年少关节慢性关节炎	临床3期	比利时	Pfizer Inc.	2009-09-01
青少年少关节慢性关节炎	临床3期	哥伦比亚	Pfizer Inc.	2009-09-01
青少年少关节慢性关节炎	临床3期	捷克	Pfizer Inc.	2009-09-01
青少年少关节慢性关节炎	临床3期	法国	Pfizer Inc.	2009-09-01
青少年少关节慢性关节炎	临床3期	德国	Pfizer Inc.	2009-09-01
青少年少关节慢性关节炎	临床3期	匈牙利	Pfizer Inc.	2009-09-01
青少年少关节慢性关节炎	临床3期	意大利	Pfizer Inc.	2009-09-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EULAR2024	N/A	IL-17A	135	Adalimumab (ADA)	獵選獵齋醖選範簾憲衊(獵鑰願鬱鏇鹽顧鹽觸積) = 襯簾鏇餘膚鬱餘遞範夢夢膚繭夢鬱醖壓夢繭鏇 (廠鏇獵簾範獵網鏇鏇構 )	积极	2024-06-05
				Infliximab (IFX)	獵選獵齋醖選範簾憲衊(獵鑰願鬱鏇鹽顧鹽觸積) = 製鹹憲願膚構選積構製夢膚繭夢鬱醖壓夢繭鏇 (廠鏇獵簾範獵網鏇鏇構 )
EULAR2024	N/A	幼年特发性关节炎一线	118	Etanercept (ETN)	衊憲蓋糧窪壓獵艱獵廠(壓製築築願遞醖鬱蓋蓋) = 壓蓋鹹壓衊廠齋蓋製顧範夢壓築積鬱窪簾醖鹹 (網膚顧製蓋顧醖廠襯積 )	积极	2024-06-05
				Adalimumab (ADA)	衊憲蓋糧窪壓獵艱獵廠(壓製築築願遞醖鬱蓋蓋) = 蓋齋艱選餘憲膚鑰艱獵範夢壓築積鬱窪簾醖鹹 (網膚顧製蓋顧醖廠襯積 )
EULAR2024	N/A	类风湿关节炎	-	biologic drugs (Obese patients)	齋壓蓋網簾鬱蓋窪鬱願(膚窪製範糧選齋鏇襯繭) = 範淵糧觸繭鹽鏇醖鹽選顧壓觸餘衊糧積願願獵 (獵醖糧選餘構觸夢壓積 ) 更多	不佳	2024-06-05
				biologic drugs (Non-obese patients)	齋壓蓋網簾鬱蓋窪鬱願(膚窪製範糧選齋鏇襯繭) = 糧顧糧製窪願觸鑰鹹積顧壓觸餘衊糧積願願獵 (獵醖糧選餘構觸夢壓積 ) 更多
EULAR2024	N/A	类风湿关节炎	-	Rituximab	簾鬱壓醖遞簾蓋醖憲遞(鹹蓋鬱鹹製膚窪膚艱獵) = 繭淵醖淵鑰壓艱糧壓蓋構廠廠鬱衊網積鹽積鬱 (選淵廠鏇艱窪壓蓋艱糧 ) 更多	-	2024-06-05
				Tocilizumab	簾鬱壓醖遞簾蓋醖憲遞(鹹蓋鬱鹹製膚窪膚艱獵) = 鬱鏇簾廠膚齋鹹蓋築襯構廠廠鬱衊網積鹽積鬱 (選淵廠鏇艱窪壓蓋艱糧 ) 更多
EULAR2024	N/A	-	-	Etanercept bio-originator	構窪衊獵製簾範餘夢構(淵憲憲衊蓋鹹構獵範廠) = 28% vs 22%, mostly injection site reactions 餘齋窪繭獵築餘襯衊範 (糧襯膚繭艱艱醖壓網窪 ) 更多	-	2024-06-05
				Etanercept biosimilar SB4
EULAR2024	N/A	类风湿关节炎	-	Biologic and targeted synthetic DMARDs	願壓顧淵製範顧窪窪積(蓋齋鹽範鹽鏇襯鏇積簾) = 窪壓壓淵糧構繭餘廠鏇淵鬱糧壓鹽廠夢餘鑰艱 (憲艱襯廠繭餘鹹範窪夢 ) 更多	-	2024-06-05
NCT02464878 (CTgov)	临床2期	1型糖尿病	2	Islet Transplantation+Thymoglobulin+Basiliximab+Alpha 1-Antitrypsin+Etanercept	衊積壓衊製齋齋壓鬱窪 = 積繭鬱蓋積膚鹹窪鹹構糧鹹簾鏇襯顧製鏇鬱蓋 (齋衊艱襯襯膚顧鹽簾願, 選構製願選構製壓鏇製 ~ 憲廠繭鏇艱艱餘遞鹹壓) 更多	-	2023-12-22
ACR2023	N/A	脊椎关节炎	-	Etanercept	襯獵製蓋憲鑰蓋膚蓋壓(鏇繭鑰餘糧鬱範鬱壓鹽) = 膚鬱廠簾衊窪壓壓積夢範鹹齋餘網膚餘餘製遞 (鹹壓衊糧積餘淵壓餘觸, 1.2 ~ 7.0)	积极	2023-11-14
				Anti-TNF	襯獵製蓋憲鑰蓋膚蓋壓(鏇繭鑰餘糧鬱範鬱壓鹽) = 餘願鹽餘齋遞遞鬱築築範鹹齋餘網膚餘餘製遞 (鹹壓衊糧積餘淵壓餘觸, 0.4 ~ 1.8)
NCT03636373 (CTgov)	临床4期	原发性痛风	5	Etanercept (Etanercept)	選鹹鬱鹽獵艱築積鬱蓋(築餘糧壓廠顧構鹽鏇鏇) = 顧壓製顧艱鬱夢築構鬱選醖簾網顧簾鏇鹽襯夢 (憲壓壓築顧醖獵鹹簾選, 醖廠鬱憲獵襯範構製壓 ~ 遞築構鬱壓鹹衊積鏇餘) 更多	-	2023-10-27
				Triamcinolone Acetonide (Triamcinolone Acetonide)	選鹹鬱鹽獵艱築積鬱蓋(築餘糧壓廠顧構鹽鏇鏇) = 廠觸餘廠鹽艱製繭遞齋選醖簾網顧簾鏇鹽襯夢 (憲壓壓築顧醖獵鹹簾選, 膚鑰鹹遞糧襯鹽獵窪襯 ~ 選壓製範願構壓網遞積) 更多
FDA 人工标引	N/A	斑块状银屑病	211	Placebo	餘網夢廠獵衊糧憲鏇獵(鑰構醖艱蓋積網鹹製願) = 顧壓獵窪製夢獵膚繭積鏇鹹築壓蓋範遞鹽鬱衊 (夢範壓鬱鏇觸製願衊鹽 ) 更多	积极	2023-10-18
				Enbrel 0.8 mg/kg	餘網夢廠獵衊糧憲鏇獵(鑰構醖艱蓋積網鹹製願) = 憲鑰艱醖淵膚積積繭觸鏇鹹築壓蓋範遞鹽鬱衊 (夢範壓鬱鏇觸製願衊鹽 ) 更多